RhumbLine Advisers
CGON icon

RhumbLine Advisers’s CG Oncology CGON Stock Holding History

RhumbLine Advisers’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.45M Buy
90,849
+19,767
+28% +$1.29M ﹤0.01% 1340
2026
Q1 		$4.81M Buy
71,082
+481
+0.7% +$27.3K ﹤0.01% 1415
2025
Q4 		$2.93M Sell
70,601
-10,157
-13% -$420K ﹤0.01% 1670
2025
Q3 		$3.25M Sell
80,758
-1,666
-2% -$48.4K ﹤0.01% 1644
2025
Q2 		$2.14M Buy
82,424
+7,735
+10% +$186K ﹤0.01% 1847
2025
Q1 		$1.83M Buy
74,689
+5,673
+8% +$160K ﹤0.01% 1850
2024
Q4 		$1.98M Buy
69,016
+1,458
+2% +$49.9K ﹤0.01% 1883
2024
Q3 		$2.55M Buy
67,558
+33,329
+97% +$1.17M ﹤0.01% 1773
2024
Q2 		$1.08M Buy
34,229
+3,940
+13% +$137K ﹤0.01% 2199
2024
Q1 		$1.33M Buy
+30,289
New +$1.24M ﹤0.01% 2102

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RhumbLine Advisers's CGON Position: Q2 2026 in Review

RhumbLine Advisers increased its CG Oncology (CGON) stake by 28% in Q2 2026, buying an estimated $1.29M and bringing the position to 90,849 shares worth $6.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

RhumbLine Advisers first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • RhumbLine Advisers held 90,849 shares of CG Oncology worth $6.45M as of Q2 2026.
  • RhumbLine Advisers bought 19,767 CG Oncology shares in Q2 2026, an estimated $1.29M.
  • CG Oncology made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1340 holding.
  • RhumbLine Advisers first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.